Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;60(12):3063-3066.
doi: 10.1080/10428194.2019.1622098. Epub 2019 Jun 4.

Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells

Lisa S Chen  1 , Michael J Keating  2 , William G Wierda  2 , Varsha Gandhi  1   2
Affiliations

Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells

Lisa S Chen et al. Leuk Lymphoma. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2019.1622098.

Figures

Figure 1.
Figure 1.
Biological and molecular effect of MCL-1 inhibitor A-1210477 in primary cells from patients with CLL. (A) Selectivity of A-1210477 against BCL-2 family proteins. Graphical representation of (B) percentage of annexin-V positive CLL cells cultured with vehicle DMSO alone or 3, 10, 30 μM of A-1210477 or 5–10 nM ABT-199 for 24h. Cells from peripheral blood of eight patients were cultured and analyzed by flow cytometry after staining with annexin. (C) Mean and SEM levels of apoptosis induction shown in (B). Statistical significance (*p < .05) was determined using a two-tailed paired t-test (GraphPad Prism software). (D) Immunoblot analysis of apoptosis-related and BCL-2 family proteins in CLL cells from two patients treated in vitro as described in (B).
Figure 2.
Figure 2.
Biological and molecular effect of MCL-1 inhibitor S63845 at nanomolar concentrations in primary cells from patients with CLL. (A) Selectivity of S63845 against BCL-2 family proteins. Graphical representation of (B) percentage of annexin-V positive CLL cells cultured with 10, 30, or 100 nM S63845. Cells from peripheral blood of seven patients were cultured and analyzed by flow cytometry after staining with annexin. (C) Mean and SEM levels of apoptosis induction shown in (B). Statistical significance (*p < .05) was determined using a two-tailed paired t-test. (D) Immunoblot analysis of apoptosis-related and BCL-2 family proteins in CLL cells from four patients treated as described in (B).
See this image and copyright information in PMC

References

    1. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488–496. - PMC - PubMed
    1. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–1120. - PubMed
    1. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778. - PubMed
    1. Besbes S, Pocard M, Mirshahi M, et al. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2016;100: 32–36. - PubMed
    1. Choudhary GS, Al-Harbi S, Mazumder S, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources